Daraxonrasib in pancreatic cancer treatment: in some patients tumors stopped being visible
The daraxonrasib pill, given with chemotherapy in a clinical trial, halted tumor growth in nearly all participants with advanced pancreatic cancer. Doctors stress that the duration of its effectiveness remains unknown.

- 0views
- 0likes and saves
- 0skips
In brief
- The drug daraxonrasib, given with chemotherapy, stopped tumour growth in nearly all of the 61 participants with advanced pancreatic cancer.
- In every twelfth patient, the tumour was no longer visible on imaging scans.
- It is not yet known how long the drug can keep the disease under control, so further research is needed.
Results of the early trial
The clinical trial involved 61 people with newly diagnosed advanced pancreatic cancer that had spread to other organs (Ogromna nadzieja w tabletce na raka trzustki. W badaniu klinicznym guzy zniknęły – RMF24). In every twelfth patient treated with daraxonrasib combined with chemotherapy, the cancer was no longer visible on imaging scans.
Why it matters
Pancreatic cancer is one of the deadliest cancers and is difficult to treat. The drug is taken daily in tablet form.
Doctors' caution
Specialists stress that it is not known how long daraxonrasib can keep the disease under control. For this reason, it should not be regarded as a drug that guarantees a cure. The organisation Cancer Research UK considered the finding a breakthrough, but pointed to the need for further research.
What next
These results come from an early stage of research, and effectiveness in a larger group of patients must be confirmed in subsequent phases. People diagnosed with pancreatic cancer should discuss the available treatment options with their oncologist.
Sources
Discussion0
- No comments from this perspective yet. Be the first.
